Abstract
Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce cardiorenal events, but their association with insulin resistance in routine care is incompletely characterised, particularly where medication records cannot exclude exogenous insulin use. In this prospective, single-arm, single-centre cohort study, 54 adults with type 2 diabetes initiating an SGLT2 inhibitor were assessed at baseline, 3 and 6 months. Outcomes were HOMA-IR and the insulin-independent triglyceride–glucose (TyG) index within a family of 15 metabolic and laboratory variables, tested by Wilcoxon signed-rank test with Benjamini–Hochberg control and summarised as the rank-biserial correlation. Median HOMA-IR fell from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), −62.6% (r = −0.79, adjusted p < 0.001), and the TyG index from 9.45 to 9.04 (−4.3%, r = −0.63, adjusted p < 0.001). Haemoglobin rose 5.0%, consistent with plasma-volume contraction. Change in HOMA-IR did not track change in HbA1c (ρ = −0.15, p = 0.27). An exploratory kidney-disease × time interaction was nominally significant for TyG (β = +0.31, p = 0.040) but not log-HOMA-IR (β = +0.39, p = 0.077). Because the design was single-arm and confounders unrecorded, these are associations observed during therapy, not treatment effects. The divergence between insulin-dependent and insulin-independent indices is relevant to endpoint selection in controlled studies.

This publication has 60 references indexed in Scilit: